Meeting
2017 Genitourinary Cancers Symposium
The effect of adjuvant chemotherapy for patients with adverse pathology after neoadjuvant chemotherapy for muscle invasive bladder cancer.
Authors
William P. Parker
Mayo Clinic, Rochester, MN
William P. Parker , Elizabeth B. Habermann , Courtney N. Day , Harras B. Zaid , Igor Frank , Robert Houston Thompson , Matthew K. Tollefson , Stephen A. Boorjian , Lance C. Pagliaro , Jeffrey Karnes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 367)
DOI
10.1200/JCO.2017.35.6_suppl.367
Abstract #
367
Poster Bd #
H4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Use of neoadjuvant chemotherapy in elderly patients with muscle invasive bladder cancer: A population-based study, 2006 to 2017.
First Author: Natasza Posielski
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment for MIBC.
First Author: Michael Glover
Poster
2024 ASCO Genitourinary Cancers Symposium
Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.
First Author: Ryan Michael Antar
Poster
2024 ASCO Genitourinary Cancers Symposium
Pathologic and survival outcomes following radical cystectomy for “progressive” and “de novo” muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
First Author: Leilei Xia